论文信息 - Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM). - 字舞流文

Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM).

K. Griffith | A. Jakubowiak | J. Levy | R. Vij | T. Zimmerman | M. Faham | K. Kong | D. Reece | N. Raje | S. Gurbuxani | J. Berdeja | S. Rosebeck | Mattina M Alonge | J. Jasielec | C. Rosenbaum | Kathryn McDonnell | Jessica Waite-Marin